- Home
- FTRK vs CLYM Comparison
FTRK vs CLYM Comparison
Compare FTRK & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRK
- CLYM
- Stock Information
- Founded
- FTRK 2012
- CLYM 2018
- Country
- FTRK Singapore
- CLYM United States
- Employees
- FTRK N/A
- CLYM N/A
- Industry
- FTRK
- CLYM
- Sector
- FTRK
- CLYM
- Exchange
- FTRK NYSE
- CLYM NYSE
- Market Cap
- FTRK 102.2M
- CLYM 84.5M
- IPO Year
- FTRK 2025
- CLYM 2021
- Fundamental
- Price
- FTRK $4.58
- CLYM $1.26
- Analyst Decision
- FTRK
- CLYM Buy
- Analyst Count
- FTRK 0
- CLYM 1
- Target Price
- FTRK N/A
- CLYM $10.00
- AVG Volume (30 Days)
- FTRK 2.0M
- CLYM 188.0K
- Earning Date
- FTRK 01-01-0001
- CLYM 08-13-2025
- Dividend Yield
- FTRK N/A
- CLYM N/A
- EPS Growth
- FTRK N/A
- CLYM N/A
- EPS
- FTRK N/A
- CLYM N/A
- Revenue
- FTRK $117,230.00
- CLYM N/A
- Revenue This Year
- FTRK N/A
- CLYM N/A
- Revenue Next Year
- FTRK N/A
- CLYM N/A
- P/E Ratio
- FTRK N/A
- CLYM N/A
- Revenue Growth
- FTRK 2589.48
- CLYM N/A
- 52 Week Low
- FTRK $3.15
- CLYM $1.05
- 52 Week High
- FTRK $9.69
- CLYM $9.25
- Technical
- Relative Strength Index (RSI)
- FTRK N/A
- CLYM N/A
- Support Level
- FTRK N/A
- CLYM N/A
- Resistance Level
- FTRK N/A
- CLYM N/A
- Average True Range (ATR)
- FTRK 0.00
- CLYM 0.00
- MACD
- FTRK 0.00
- CLYM 0.00
- Stochastic Oscillator
- FTRK 0.00
- CLYM 0.00
About FTRK FAST TRACK GROUP
Fast Track Group is a regional entertainment-focused event management and marketing company that provides a full range of services including experiential marketing, artiste endorsement and management, movie premiere organizations, grand openings, and concerts. It also creates, develops, organizes, hosts, and manages various events and concerts.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.